| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.50(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
97,498 |
194,989 |
250,525 |
524,601 |
| Total Sell Value |
$1,990,812 |
$3,814,194 |
$5,260,505 |
$13,449,119 |
| Total People Sold |
2 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
19 |
37 |
75 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schenkein David P |
Director |
– • – |
2020-12-21 |
4 |
AS |
$90.01 |
$450,027 |
I/I |
(5,000) |
26,232 |
|
-36% |
|
| Schenkein David P |
Director |
– • – |
2020-12-21 |
4 |
AS |
$90.06 |
$2,251,555 |
D/D |
(25,000) |
0 |
|
-36% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-12-14 |
4 |
S |
$80.35 |
$1,432,842 |
I/I |
(17,825) |
383,411 |
|
27% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-12-11 |
4 |
S |
$80.05 |
$3,746,442 |
I/I |
(46,799) |
401,236 |
|
29% |
|
| Schenkein David P |
Director |
– • – |
2020-11-12 |
4 |
AS |
$70.05 |
$2,101,590 |
D/D |
(30,000) |
25,000 |
|
-21% |
|
| Schenkein David P |
Director |
– • – |
2020-11-10 |
4 |
AS |
$60.03 |
$600,310 |
D/D |
(10,000) |
55,000 |
|
-3% |
|
| Schenkein David P |
Director |
– • – |
2020-11-04 |
4 |
AS |
$50.18 |
$501,830 |
D/D |
(10,000) |
65,000 |
|
25% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-10-09 |
4 |
AS |
$40.68 |
$1,236,614 |
I/I |
(30,000) |
166,617 |
|
51% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-10-09 |
4 |
OE |
$5.28 |
$158,400 |
I/I |
30,000 |
196,617 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-10-08 |
4 |
AS |
$40.12 |
$918,989 |
I/I |
(22,906) |
166,617 |
|
63% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-10-08 |
4 |
OE |
$5.28 |
$120,944 |
I/I |
22,906 |
189,523 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2020-09-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
13,310,243 |
|
90% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-09-10 |
4 |
AS |
$31.00 |
$114,359 |
I/I |
(3,689) |
165,141 |
|
147% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2020-08-21 |
4 |
D |
$32.88 |
$64,248 |
I/I |
(1,954) |
614,562 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-08-21 |
4 |
D |
$32.88 |
$64,248 |
D/D |
(1,954) |
6,511 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-08-21 |
4 |
D |
$32.87 |
$64,228 |
I/I |
(1,954) |
1,006,511 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,643 |
616,516 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,643 |
8,465 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,643 |
1,008,465 |
|
- |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2020-08-12 |
4 |
S |
$31.65 |
$45,678,768 |
I/I |
(1,443,247) |
12,201,634 |
|
-194% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-30 |
4 |
S |
$24.01 |
$1,088,601 |
I/I |
(45,345) |
448,035 |
|
-148% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-29 |
4 |
S |
$23.84 |
$1,982,373 |
I/I |
(82,578) |
493,380 |
|
-135% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-26 |
4 |
S |
$23.84 |
$2,922,078 |
I/I |
(122,077) |
575,958 |
|
-128% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-23 |
4 |
S |
$25.69 |
$515,969 |
I/I |
(20,024) |
698,035 |
|
-75% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-22 |
4 |
S |
$24.66 |
$2,231,902 |
I/I |
(90,056) |
718,059 |
|
-76% |
|
416 Records found
|
|
Page 10 of 17 |
|
|
1.11 (5.62%) 
